Table of Contents PART 01: Executive summary PART 02: Scope of  the report Market overview Top-vendor offerings PART 03: Market research methodology Research methodology Economic indicators PART 04: Introduction Key market highlights Highlights PART 05: Disease overview Diagnosis of VTE Treatment of VTE PART 06: Pipeline analysis PART 07: Market landscape Market overview Five forces analysis PART 08: Market segmentation by drug class Factor Xa inhibitors Direct thrombin inhibitors Heparin Vitamin K antagonists PART 09: Geographical segmentation VTE therapeutics market in Americas VTE therapeutics market in EMEA VTE therapeutics market in APAC PART 10: Market drivers Increasing adoption of NOACs Increasing surgical procedures such as hip and knee replacements Large patient pool coupled with growing awareness campaigns PART 11: Impact of drivers PART 12: Market challenges Presence of alternatives such as thrombectomy and percutaneous techniques Unmet needs for anticoagulant reversal agents Extensive use of generic products PART 13: Impact of drivers and challenges PART 14: Market trends Development of drugs for new indications Growing focus on emerging economies Patient assistance programs PART 15: Vendor landscape Competitive scenario PART 16: Key vendor analysis Bayer HealthCare BMS Boehringer Ingelheim Daiichi Sankyo Johnson & Johnson Sanofi Other prominent vendors PART 17: Appendix List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Types of venous thromboembolism Exhibit 03: Pipeline analysis Exhibit 04: Key pipeline molecules Exhibit 05: Global VTE therapeutics market snapshot Exhibit 06: Global VTE therapeutics market 2016-2021 ($ millions) Exhibit 07: Opportunity analysis in global venous thromboembolism market Exhibit 08: Five forces analysis Exhibit 09: Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions) Exhibit 10: Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions) Exhibit 11: Heparin in global VTE therapeutics market 2016-2021 ($ millions) Exhibit 12: Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions) Exhibit 13: Segmentation of global VTE therapeutics market based on geography 2016 and 2021 Exhibit 14: VTE therapeutics market revenue by geography 2016-2021 (%) Exhibit 15: Market scenario in Americas Exhibit 16: VTE therapeutics market in Americas 2016-2021 ($ millions) Exhibit 17: Market scenario in EMEA Exhibit 18: VTE therapeutics market in EMEA ($ millions) Exhibit 19: Market scenario in APAC Exhibit 20: Venous thromboembolism therapeutics market in APAC ($ millions) Exhibit 21: Impact of drivers Exhibit 22: Forcefield analysis of drivers and challenges Exhibit 23: Impact of drivers and challenges Exhibit 24: Competitive structure analysis of global VTE therapeutics market 2015 Exhibit 25: Competitive analysis of global VTE therapeutics market 2016 Exhibit 26: Market share analysis 2015 Exhibit 27: Market penetration of various VTE manufacturers worldwide 2016 Exhibit 28: Strategic success factors of companies in global VTE therapeutics market Exhibit 29: Bayer HealthCare: Key highlights Exhibit 30: Bayer HealthCare: Strength assessment Exhibit 31: Bayer HealthCare: Strategy assessment Exhibit 32: Bayer HealthCare: Opportunity assessment Exhibit 33: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions) Exhibit 34: BMS: Key highlights Exhibit 35: BMS: Strength assessment Exhibit 36: BMS: Strategy assessment Exhibit 37: BMS: Opportunity assessment Exhibit 38: BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions) Exhibit 39: Geographic segmentation of Eliquis 2015 Exhibit 40: Boehringer Ingelheim: Key highlights Exhibit 41: Boehringer Ingelheim: Strength assessment Exhibit 42: Boehringer Ingelheim: Strategy assessment Exhibit 43: Boehringer Ingelheim: Opportunity assessment Exhibit 44: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions) Exhibit 45: Daiichi Sankyo: Key highlights Exhibit 46: Daiichi Sankyo: Strength assessment Exhibit 47: Daiichi Sankyo: Strategy assessment Exhibit 48: Daiichi Sankyo: Opportunity assessment Exhibit 49: Johnson & Johnson: Key highlights Exhibit 50: Johnson & Johnson: Strength assessment Exhibit 51: Johnson & Johnson: Strategy assessment Exhibit 52: Johnson & Johnson: Opportunity assessment Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions) Exhibit 54: Sanofi: Key highlights Exhibit 55: Sanofi: Strength assessment Exhibit 56: Sanofi: Strategy assessment Exhibit 57: Sanofi: Opportunity assessment Exhibit 58: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions) Exhibit 59: Geographical segmentation of Lovenox 2015

Bayer HealthCare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Sanofi, Altor Bioscience, Armetheon, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals, Gamma Therapeutics, GlycoMimetics, Green Cross, Isis Pharmaceutical, Leo Pharma, Pfizer, Portola Pharmaceuticals, ThromboGenics.